Plasma Therapy Market  Report Scope & Overview:

The Plasma Therapy Market Size was valued at USD 416.83 billion in 2022, and is expected to reach USD 836.69 billion by 2030, and grow at a CAGR of 9.1% over the forecast period 2023-2030.

Plasma, platelets, red blood cells, and white blood cells make up the blood. Plasma makes up over 57% of the entire blood volume. Important hormones, proteins, and nutrients are transported by the plasma to many bodily areas. The fundamental goal of plasma therapy is to give a patient access to a healthy person's immune. The plasma typically has a high concentration of antibodies, which aids in the treatment of the illness.

Plasma Therapy Market Revenue Analysis

Get more information on Plasma Therapy Market - Request Sample Report

Proteins that are lacking or insufficient can be replaced by plasma treatment, enabling people to live healthy, disorder-free lives. Human blood provides various plasma-derived remedies for crippling, ongoing, and life-threatening illnesses as a result of expanding plasma-fractionation procedures. Plasma-derived products are essential for prevention and medical treatment. Plasma products are essential for treating autoimmune disorders, a variety of chronic illnesses such hemophilia, congenital and acquired immunodeficiencies, and bleeding emergencies. The market for plasma therapy is expanding as a result of improved access to healthcare, new goods and uses, and diagnostic advancements.



  • Sports injuries are occurring more frequently.

  • Global Androgenic Alopecia Patient Numbers are on the Rise

  • Increasing Application of Platelet-Rich Plasma in a Variety of Therapeutic Fields

  • Arthritis frequency


  • Absence of Policies for Reimbursement

  • Different Plasma Therapy Costs


  • A rise in the number of people afflicted with orthopedic conditions and androgenic alopecia


  • Patients with diabetes and kidney diseases cannot use PRP without restrictions

  • Additional Regenerative Medicine Developments


The COVID-19 pandemic outbreak and government-ordered lockdowns to stop the disease's spread had an effect on a number of businesses. Due to the hospitals' inadequate staff and resources in comparison to the unexpected increase in the number of infected patients, the spike in infected patients had an influence on hospital administration. This resulted in a delay in medical treatments and surgeries. The non-emergency medical operation was postponed, and priority was given to emergency treatments that were more likely to impact patients or result in fatalities if postponed.

The plasma supply was put under further strain by the COVID-19 epidemic. The unexpected increase in COVID-19 patients has an impact on businesses, suppliers, and owners of platelet-rich plasma (PRP) therapeutic items in Asian economies. The absence of health infrastructure and government rules put on businesses and suppliers created problems for the middle- and low-income countries. Because there were no vaccines, other specialised medications, or treatments available during the pandemic, plasma therapy was suggested as a treatment.

By Type

Due to the minimal or nonexistent dangers associated with the use of pure PRP, the pure PRP category exhibits the biggest revenue share of the global market. Pure platelet-rich plasma is a preparation that has less red blood cells and concentrated platelet growth factors. It shows positive results in the treatment of patients' illnesses. The method is strongly advised.

Leukocyte-Rich PRP: PRP that is high in leukocytes is used to treat osteoarthritis in the hips and knees. A preparation with a high proportion of leukocytes is called leukocyte-rich PRP. Its primary purpose is to aid in the repair of ligaments and tendons.

Pure Platelet-Rich Fibrin: It's utilised to encourage wound healing, bone regeneration, transplant stabilization, and hemostasis. Platelet-rich fibrin and autologous leukocytes produced from patient blood can be used to define it.

Leukocyte-Rich Fibrin is an autologous platelet concentrate that has an increased fibrin matrix made up of platelets, leukocytes, and an excess of growth factors and cytokines.

By Source

Autologous: In 2021, this market category will hold the lion's share of the market. The market development of the autologous source segment is being driven by the widespread acceptance of plasma therapy as a potential treatment for bones and tissues in need of mending.

Allogenic: When compared to whole blood, allogeneic PRP contains 4.1 times as many platelets and growth regulators, respectively.

By Application

Dermatology: During the projection period, the segment is anticipated to have the greatest CAGR. This can be linked to an increase in the number of patients with hair- and skin-related disorders, a rise in the general public's awareness of beauty, and an increase in the usage of micro needling for cosmetic procedures.

Orthopedic: The market sector is expanding quickly due in large part to the increase in individuals suffering from bone-related illnesses such as arthritis. These disorders affect the bones and limbs.

Heart Muscle Injury: The cardiac muscles are treated using plasma. The repair of cardiac muscles is aided by plasma.

By End-users

Hospitals & Clinics: The treatment of illnesses like COVID-19, autoimmune disorders, cardiac-related ailments, and others is done in hospitals using plasma therapy.

Research Institutes: In order to develop a cure for common and dangerous diseases, research institutes use plasma from various patients.


By Type

  • Pure PRP

  • Leukocyte-Rich PRP

  • Pure Platelet-Rich Fibrin

  • Leukocyte-Rich Fibrin

By Source

  • Autologous

  • Allogenic

By Application

  • Orthopedic

  • Dermatology

  • Cardiac Muscle Injury

  • Dental

  • Nerve Injury

By End-users

  • Hospitals & Clinics

  • Research Institutes

Plasma Therapy Market Segmentation Analysis

Need any customization research on Plasma Therapy Market - Enquiry Now


During the projection period, North America is anticipated to have a significant market share for plasma therapy worldwide. Due to increased government and private sector research and development, it is projected that the market in the region would expand in the future. Due to growing populations and increased public awareness of blood donation, Asia-Pacific is also expected to experience significant growth. The expansion of hospitals and clinics as well as the availability of cutting-edge plasma therapies fuel the plasma therapy market.


  • North America

    • USA

    • Canada

    • Mexico

  • Europe

    • Germany

    • UK

    • France

    • Italy

    • Spain

    • The Netherlands

    • Rest of Europe

  • Asia-Pacific

    • Japan

    • south Korea

    • China

    • India

    • Australia

    • Rest of Asia-Pacific

  • The Middle East & Africa

    • Israel

    • UAE

    • South Africa

    • Rest of Middle East & Africa

  • Latin America

    • Brazil

    • Argentina

    • Rest of Latin America


Major key players are as follows: Arthrex, Terumo Corporation, Exactech, Inc., Johnson & Johnson (DePuy Synthes), MTF Biologics, Ony Biotech Inc., Pfizer Inc., Regen Lab SA, Teva Pharmaceutical Industries Ltd., Zimmer Biomet and other players.

Ony Biotech Inc-Company Financial Analysis

Company Landscape Analysis

Plasma Therapy Market Report Scope:

Report Attributes Details
Market Size in 2022 US$ 416.83 Billion
Market Size by 2030 US$ 836.69 Billion
CAGR CAGR of 9.1% From 2023 to 2030
Base Year 2022
Forecast Period 2023-2030
Historical Data 2020-2021
Report Scope & Coverage Market Size, Segments Analysis, Competitive  Landscape, Regional Analysis, DROC & SWOT Analysis, Forecast Outlook
Key Segments • by Type (Pure PRP, Leukocyte-Rich PRP, Pure Platelet-Rich Fibrin, Leukocyte-Rich Fibrin)
• By Source (Autologous, Allogenic)
• By Application (Orthopedic, Dermatology, Cardiac Muscle Injury, Dental, Nerve Injury)
• By End-users (Hospitals & Clinics, Research Institutes)
Regional Analysis/Coverage North America (USA, Canada, Mexico), Europe
(Germany, UK, France, Italy, Spain, Netherlands,
Rest of Europe), Asia-Pacific (Japan, South Korea,
China, India, Australia, Rest of Asia-Pacific), The
Middle East & Africa (Israel, UAE, South Africa,
Rest of Middle East & Africa), Latin America (Brazil, Argentina, Rest of Latin America)
Company Profiles Arthrex, Terumo Corporation, Exactech, Inc., Johnson & Johnson (DePuy Synthes), MTF Biologics, Ony Biotech Inc., Pfizer Inc., Regen Lab SA, Teva Pharmaceutical Industries Ltd., Zimmer Biomet.
Key Drivers • Sports injuries are occurring more frequently.
• Global Androgenic Alopecia Patient Numbers are on the Rise.
RESTRAINTS • Absence of Policies for Reimbursement
• Different Plasma Therapy Costs

Frequently Asked Questions

 Ans. The Plasma Therapy market size was valued at US$ 416.83 billion in 2022.

Ams: The Plasma Therapy market is to grow at a CAGR of 9.1% over the forecast period 2023-2030.

Ans The plasma supply was put under further strain by the COVID-19 epidemic. The unexpected increase in COVID-19 patients has an impact on businesses, suppliers, and owners of platelet-rich plasma (PRP) therapeutic items in Asian economies.

Ans. Arthrex, Terumo Corporation, Exactech, Inc., Johnson & Johnson (DePuy Synthes), MTF Biologics, Ony Biotech Inc., Pfizer Inc. are the key players of the Plasma Therapy Market

 Ans. Dermatology During the projection period, the segment is anticipated to have the greatest CAGR.

Table of Contents

1. Introduction

1.1 Market Definition

1.2 Scope

1.3 Research Assumptions

2. Research Methodology

3. Market Dynamics

3.1 Drivers

3.2 Restraints

3.3 Opportunities

3.4 Challenges

4. Impact Analysis

4.1 COVID-19 Impact Analysis

4.2 Impact of Ukraine- Russia War

4.3 Impact of Ongoing Recession

4.3.1 Introduction

4.3.2 Impact on major economies US Canada Germany France United Kingdom China Japan South Korea Rest of the World

5. Value Chain Analysis

6. Porter’s 5 forces model

7.  PEST Analysis


8. Plasma Therapy Market Segmentation, By Type

8.1 Pure PRP

8.2 Leukocyte-Rich PRP

8.3 Pure Platelet-Rich Fibrin

8.4 Leukocyte-Rich Fibrin

9. Plasma Therapy Market Segmentation, By Source

9.1 Autologous

9.2 Allogenic

10. Plasma Therapy Market Segmentation, By Application

10.1 Orthopedic

10.2 Dermatology

10.3 Cardiac Muscle Injury

10.4 Dental

10.5 Nerve Injury

11. Plasma Therapy Market Segmentation, By End-users

11.1 Hospitals & Clinics

11.2 Research Institutes

12. Regional Analysis

12.1 Introduction

12.2 North America

12.2.1 USA

12.2.2 Canada

12.2.3 Mexico

12.3 Europe

12.3.1 Germany

12.3.2 UK

12.3.3 France

12.3.4 Italy

12.3.5 Spain

12.3.6 The Netherlands

12.3.7 Rest of Europe

12.4 Asia-Pacific

12.4.1 Japan

12.4.2 South Korea

12.4.3 China

12.4.4 India

12.4.5 Australia

12.4.6 Rest of Asia-Pacific

12.5 The Middle East & Africa

12.5.1 Israel

12.5.2 UAE

12.5.3 South Africa

12.5.4 Rest

12.6 Latin America

12.6.1 Brazil

12.6.2 Argentina

12.6.3 Rest of Latin America

13.Company Profiles

13.1 Arthrex

13.1.1 Financial

13.1.2 Products/ Services Offered

13.1.3 SWOT Analysis

13.1.4 The SNS view

13.2 Terumo Corporation

13.3 Exactech, Inc.

13.4 Johnson & Johnson (DePuy Synthes)

13.5 MTF Biologics

13.6 Ony Biotech Inc.

13.7 Pfizer Inc.

13.8 Regen Lab SA

13.9 Teva Pharmaceutical Industries Ltd.

13.10 Zimmer Biomet

14.Competitive Landscape

14.1 Competitive Benchmark

14.2 Market Share Analysis

14.3 Recent Developments


An accurate research report requires proper strategizing as well as implementation. There are multiple factors involved in the completion of good and accurate research report and selecting the best methodology to compete the research is the toughest part. Since the research reports we provide play a crucial role in any company’s decision-making process, therefore we at SNS Insider always believe that we should choose the best method which gives us results closer to reality. This allows us to reach at a stage wherein we can provide our clients best and accurate investment to output ratio.

Each report that we prepare takes a timeframe of 350-400 business hours for production. Starting from the selection of titles through a couple of in-depth brain storming session to the final QC process before uploading our titles on our website we dedicate around 350 working hours. The titles are selected based on their current market cap and the foreseen CAGR and growth.


The 5 steps process:

Step 1: Secondary Research:

Secondary Research or Desk Research is as the name suggests is a research process wherein, we collect data through the readily available information. In this process we use various paid and unpaid databases which our team has access to and gather data through the same. This includes examining of listed companies’ annual reports, Journals, SEC filling etc. Apart from this our team has access to various associations across the globe across different industries. Lastly, we have exchange relationships with various university as well as individual libraries.

Secondary Research

Step 2: Primary Research

When we talk about primary research, it is a type of study in which the researchers collect relevant data samples directly, rather than relying on previously collected data.  This type of research is focused on gaining content specific facts that can be sued to solve specific problems. Since the collected data is fresh and first hand therefore it makes the study more accurate and genuine.

We at SNS Insider have divided Primary Research into 2 parts.

Part 1 wherein we interview the KOLs of major players as well as the upcoming ones across various geographic regions. This allows us to have their view over the market scenario and acts as an important tool to come closer to the accurate market numbers. As many as 45 paid and unpaid primary interviews are taken from both the demand and supply side of the industry to make sure we land at an accurate judgement and analysis of the market.

This step involves the triangulation of data wherein our team analyses the interview transcripts, online survey responses and observation of on filed participants. The below mentioned chart should give a better understanding of the part 1 of the primary interview.

Primary Research

Part 2: In this part of primary research the data collected via secondary research and the part 1 of the primary research is validated with the interviews from individual consultants and subject matter experts.

Consultants are those set of people who have at least 12 years of experience and expertise within the industry whereas Subject Matter Experts are those with at least 15 years of experience behind their back within the same space. The data with the help of two main processes i.e., FGDs (Focused Group Discussions) and IDs (Individual Discussions). This gives us a 3rd party nonbiased primary view of the market scenario making it a more dependable one while collation of the data pointers.

Step 3: Data Bank Validation

Once all the information is collected via primary and secondary sources, we run that information for data validation. At our intelligence centre our research heads track a lot of information related to the market which includes the quarterly reports, the daily stock prices, and other relevant information. Our data bank server gets updated every fortnight and that is how the information which we collected using our primary and secondary information is revalidated in real time.

Data Bank Validation

Step 4: QA/QC Process

After all the data collection and validation our team does a final level of quality check and quality assurance to get rid of any unwanted or undesired mistakes. This might include but not limited to getting rid of the any typos, duplication of numbers or missing of any important information. The people involved in this process include technical content writers, research heads and graphics people. Once this process is completed the title gets uploader on our platform for our clients to read it.

Step 5: Final QC/QA Process:

This is the last process and comes when the client has ordered the study. In this process a final QA/QC is done before the study is emailed to the client. Since we believe in giving our clients a good experience of our research studies, therefore, to make sure that we do not lack at our end in any way humanly possible we do a final round of quality check and then dispatch the study to the client.

Start a Conversation

Hi! Click one of our member below to chat on Phone